Fresenius Medical Care Q2 Operating Income Beats Consensus by 10%, Margin Expands to 11.7%
FMS sits 27% above its 52-week low of $20.02.
Summary
Fresenius Medical Care reported Q2 2026 results with adjusted operating income up 23% at constant currency, beating consensus by 10%. Revenue grew 5% organically, and the company reaffirmed its full-year outlook.
Key Events · Earnings and Guidance · FMS
-
Q2 Earnings Beat
Operating income excluding special items rose 23% at constant currency to €569M, beating consensus by 10%. Revenue grew 5% organically to €4,861M.
-
Margin Expansion
Adjusted operating margin expanded to 11.7% from 9.9% a year ago, driven by Care Delivery's 45% constant-currency income growth and FME25+ savings.
-
EPS Growth
Adjusted basic EPS increased 28% at constant currency to €1.13, supported by the share buyback program that reduced the share count by 8.5%.
-
5008X CAREsystem Rollout
227 U.S. clinics now use the 5008X system, with over 600,000 treatments performed. Early data shows 40% fewer muscle cramps with HVHDF modality.
Analysis · FMS · Industrial Applications And Services
A strong second quarter saw adjusted operating income surge 23% at constant currency, handily beating consensus estimates. Organic revenue grew 5%, with all segments contributing, while adjusted EPS jumped 28%, aided by the ongoing share buyback. The rollout of the 5008X CAREsystem is accelerating—now in 227 U.S. clinics—and management reaffirmed the full-year outlook, signaling confidence in sustained momentum despite currency headwinds and one-time charges from portfolio optimization.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 29.2% of the 1581 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FMS was trading at $25.36 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $13.6B. The 52-week trading range was $20.02 to $27.64. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.